The proposed allottees are promoter Dr Abhinay Bollineni, who will receive 32.09 lakh warrants, promoter Adwik Bollineni, who will receive 32.09 lakh warrants, and promoter group entity Bharas Ventures LLP, which will receive 12.84 lakh warrants.
Also Read: KIMS to set up 300-bed super specialty hospital in Chennai with ₹300 crore investmentThe aggregate consideration receivable from the issue is about ₹600 crore. Dr Abhinay Bollineni and Adwik Bollineni will each contribute about ₹250 crore, while Bharas Ventures LLP will contribute ₹100 crore.
The company said the warrant issue price of ₹779 per warrant is not less than the floor price determined under applicable SEBI regulations and is based on a valuation report from a registered valuer. The relevant date for determining the issue price was June 9, 2026.Following full conversion of the warrants, Dr Abhinay Bollineni’s shareholding will increase to 34.46 lakh shares from 2.36 lakh shares, while Adwik Bollineni’s shareholding will rise to 32.50 lakh shares from 40,640 shares.
Also Read: KIMS expects average revenue per occupied bed to rise with expansion in Maharashtra and Bengaluru
Bharas Ventures LLP, which currently holds no shares, will hold 12.84 lakh shares after conversion. The promoter and promoter group’s overall shareholding is expected to increase to 35.35% from 34.11%, assuming full conversion of the warrants.
Krishna Institute of Medical Sciences said 25% of the warrant issue price will be payable at the time of subscription and allotment, with the remaining 75% payable upon conversion. If the warrants are not exercised within 18 months, the entitlement will lapse, and the amount paid will be forfeited.
On Friday (June 12), shares of Krishna Institute of Medical Sciences Ltd ended at ₹787.10, up by ₹2.88, or 22.05%, on the BSE.
Also Read: KIMS raises stake in Sunshine Hospital to 75.53% with ₹148 crore investment
